Dibutyl sebacate was selected as a plasticiser in the formulation of sustained-release matrix tablets. Dibutyl sebacate was added to a dichloromethane/EC solution and subsequently spray-dried, or was mixed as a liquid with EC powder. Hydrated tablets were evaluated by frequency sweep and creep rheological tests to correlate the results with drug release.

Dibutyl Sebacate (DBS) was diluted with dimethyl sulfoxide. Estrogenic activity was measured using a yeast two-hybrid system and a fluorescence polarization system within a concentration range of 10^-7 to 10^-3 M. Yeast strain Y190 was transformed with the pGBT9-receptors and pGAD424-coactivators using the lithium acetate method, and an S9 hepatic microsomal fraction was used to implement the mediating influence of metabolic bioactivation. DBS was tested for its ability to displaceflourescent non-steroid estrogen from the estrogen receptor. A threshold of B-galactosidase activity above 0.1, greater than 50% inhibition and a 1.5 fold increase in cell growth over controls was considered estrogenic activity. DBS showed the weakest cytotoxicity among tested compounds and an IC50 value for B-galactosidase that was higher than the applicable measurement range.